Key Takeaways Rigel will report Q3 2025 earnings on Nov. 4, with revenue estimated at $61.6 million.Tavalisse demand and solid sales of Rezlidhia and Gavreto are likely to have driven RIGL's revenue growth.Investors await updates on R289 and potential new guidance amid strong product momentum.Rigel Pharmaceuticals (RIGL) is scheduled to report third-quarter 2025 results on Nov. 4, after market close. The Zacks Consensus Estimate for the to-be-reported quarter’s revenues is pegged at $61.6 million, while the ...